Auris Medical : development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders like tinnitus and hearing loss     Print Page | Close Window

Investor FAQs

We started operations in 2003.

Auris Medical Holding AG is incorporated under the laws of Switzerland.

Auris Medical Holding AG
Bahnhofstrasse 21
6300 Zug
Switzerland

The Auris Medical Holding AG ticker symbol is EARS. Our shares are traded on the NASDAQ Capital Market.

We went public in 6 July 2014 with trading of our shares starting on August 6, 2014. The issue price was USD 6.00 per share.

American Stock Transfer & Trust Company, LLC
6201 15th Avenue Brooklyn
New York, NY 11219
Phone +1(718) 921-8200
www.amstock.com

In the United States, the vast majority of shares held by a broker or an agent of that broker are registered under the name of Cede & Co., as nominee for The Depository Trust Company (which acts as depositary and clearing house for many U.S. brokerage firms and custodian banks). If your shares are held in a stock brokerage account or otherwise by a broker, bank, trust or other nominee, then Cede & Co. is considered the record or registered holder, and you are considered the beneficial owner, of those shares, and your shares are said to be held in “street name.” Street name holders generally cannot vote their shares directly and must instead instruct their broker, bank, trust or other nominee how to vote their shares in connection with shareholder meetings.

If your shares are registered directly in your name in the Company’s records, you are considered the shareholder of record with respect to those shares.

If your shares are held in “street name” and you wish to become a shareholder of record, you can instruct your broker-dealer to move your security position through the Direct Registration System (“DRS”) to American Stock Transfer & Trust Company, LLC (“AST”), the Company’s transfer agent, for direct registration on the Company’s share register held with AST. The DRS provides for electronic direct registration of securities in an investor's name on the books of a company with its transfer agent, and allows shares to be transferred between a transfer agent and broker electronically. If you later wish to sell your shares through your broker-dealer, you may instruct your broker-dealer to request that your shares be moved back to the broker-dealer through the DRS.

The Independent Proxy will vote the shares in accordance with the instructions provided by shareholders. Absent any instructions, the Independent Proxy will vote FOR all proposals submitted by the Board of Directors to the AGM.

Whilst currently not foreseen, the Board of Directors may find itself in a position where it wishes to submit new proposals or new agenda items to the AGM. You may instruct the Independent Proxy to vote “FOR”, “AGAINST” or “ABSTAIN” from voting on such new proposal or new agenda item by ticking the appropriate box (“General Instructions on new proposals of the Board of Directors/new agenda items”) of your proxy form. Absent any instruction, the Independent Proxy would vote in accordance with the Board of Directors’ proposal on any new proposals or new agenda item proposed to the AGM.

You can view our Board of Directors by visiting the Board of Directors section of our website.

You can view our management team by visiting the Management Team section of our website.

December 31

Deloitte AG, Zurich, Switzerland

We have never paid or declared any cash dividends on our shares, and we do not anticipate paying any cash dividends on our common shares in the foreseeable future.

Quarterly and annual reports, as well as other SEC filings, can be accessed in the Financial Information section of our website or directly from the SEC at www.sec.gov.

You can contact us via email at: Investors[at]aurismedical.com .
In addition, you can reach Investor Relations by calling: +41 41 729 71 94.